Prelude Capital Management’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Prelude Capital Management’s Portfolio OPNT Stock Details OPNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,400	Closed	-$10K	–	2178
2020 Q3	$10K	Sell	1,400 -67	-5%	-$595	﹤0.01%	1461
2020 Q2	$13K	Hold	1,467	–	–	﹤0.01%	1518
2020 Q1	$14K	Sell	1,467 -695	-32%	-$8.32K	﹤0.01%	1073
2019 Q4	$31K	Buy	+2,162	New	+$31.5K	﹤0.01%	1492
2019 Q2	–	Sell	-11,533	Closed	-$151K	–	2263
2019 Q1	$151K	Sell	11,533 -12,664	-52%	-$185K	0.01%	800
2018 Q4	$350K	Buy	+24,197	New	+$395K	0.02%	572

Other funds holding OPNT

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PCM

Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prelude Capital Management's OPNT Position: Q4 2020 in Review

Prelude Capital Management sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q4 2020, closing a stake of 1,400 shares — an estimated $10K sold.

Prelude Capital Management first reported a position in OPNT in Q4 2018 and held it in 6 quarters. The position peaked at $350K in Q4 2018. 29 funds tracked by Wall St. Rank hold OPNT as of Q4 2020.

Prelude Capital Management reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Prelude Capital Management sold 1,400 Opiant Pharmaceuticals, Inc. Common Stock shares in Q4 2020, an estimated $10K.
Prelude Capital Management first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 6 quarters.
Prelude Capital Management's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $350K in Q4 2018.
29 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.